BioSpace News Archive

Fentanyl transdermal patches are used for administration in opioid-tolerant patients with severe, persistent, and moderate to severe chronic pain.

The overwhelming need for novel and enhanced therapies for a variety of diseases and disorders may bring extensive growth prospects for the cell therapy technologies market during the forecast period.

The anti-parasitic drugs refers to that very particular type of medications that are meant for the purpose of treatment of various parasitic diseases, such as those caused by parasitic fungi, protozoa, helminths, ectoparasites, and amoeba amongst many others.

The global analytical standards market provides increasing public concerns related to optimum food quality and safety, increasing applications of different analytical techniques in proteomics & metabolomics, and better regulatory emphasis on efficient pollution control and monitoring are some of the important factors driving the growth of the analytical standards market.

Santhera Pharmaceuticals provides an update on its activities and is calling an Extraordinary General Meeting, which will be held on December 15, 2021, at 10:30 hrs at the domicile of the Company.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference.

Bushu Pharmaceuticals Ltd. has agreed on an expanded partnership with Amgen Inc. and Amgen K.K. to provide its “Gateway to Asia” service to four countries across the Asia-Pacific region as Amgen’s contract manufacturing organization.

Biovica, active in cancer diagnostics, announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer patients.

Selvita – one of the largest preclinical contract research organizations in Europe continues its dynamic development. Following the acquisition of Fidelta, Selvita Group achieved in the three quarters of 2021 over a two-fold increase in sales revenue comparing to the corresponding period of the previous year.

Veracyte, Inc. announced that the Swedish Medical Technologies Product Council has recommended the Prosigna Breast Cancer Assay for immediate reimbursement and clinical use in all Swedish healthcare regions without legal restrictions beginning November 22, 2021.